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Abstract
Background: Understanding the basic mechanisms and prevention of any disease pattern lies mainly on development of a
successful experimental model. Recently, engineered heart tissue (EHT) has been demonstrated to be a useful tool in
experimental transplantation. Here, we demonstrate a novel function for the spontaneously contracting EHT as an
experimental model in studying the acute ischemia-induced changes in vitro.
Methodology/Principal Findings: EHT was constructed by mixing cardiomyocytes isolated from the neonatal rats and
cultured in a ring-shaped scaffold for five days. This was followed by mechanical stretching of the EHT for another one week
under incubation. Fully developed EHT was subjected to hypoxia with 1% O2 for 6 hours after treating them with cell
protective agents such as cyclosporine A (CsA) and acetylcholine (ACh). During culture, EHT started to show spontaneous
contractions that became more synchronous following mechanical stretching. This was confirmed by the increased
expression of gap junctional protein connexin 43 and improved action potential recordings using an optical mapping
system after mechanical stretching. When subjected to hypoxia, EHT demonstrated conduction defects, dephosphorylation
of connexin-43, and down-regulation of cell survival proteins identical to the adult heart. These effects were inhibited by
treating the EHT with cell protective agents.
Conclusions/Significance: Under hypoxic conditions, the EHT responds similarly to the adult myocardium, thus making EHT
a promising material for the study of cardiac functions in vitro.
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Introduction
Understanding the basic mechanisms and prevention of any
disease pattern lies mainly on development of a successful
experimental model. Tissue engineering is a newly developed
technique that comprises of constructing a three dimensional
structure from cardiomyocytes or progenitor cells and transplant-
ing them in to in vivo reconstruction of the diseased myocardium
[1,2,3,4,5,6]. While all the studies have used EHT as a
therapeutic tool, it not known if EHT can also replace the whole
heart to study the characteristics of cardiovascular diseases in
vitro, although Zimmermann and colleagues suggested that EHT
could become a promising material to study cardiac functions in
vitro [4]. Recent development of vascularized EHT [7,8,9]
further supports our hypothesis that EHT could become a
replacement for whole heart studies under in vitro circumstances.
In this study, using advanced techniques of optical mapping along
with other conventional techniques, we demonstrate that EHT
responds similar to the whole heart under basal and stress
conditions.
Methods
One to three days old neonatal rats born to female Wistar rats
(SLC, Japan) were used. All animals received humane care in
compliance with the ‘‘Guide for the Care and Use of Laboratory
Animals’’ prepared by the Institute of Laboratory Animal
Resources and published by the National Institute of Health
(NIH Publication No. 86–23, revised 1985) and approved by the
ethical committee of Kochi Medical School, Japan.
Cell Isolation
Cardiomyocytes were isolated from neonatal Wistar rats
(postnatal day 1 to 3) by a fractionated DNase/Trypsin digestion
protocol as described earlier [1]. The resulting cell population
(50% cardiomoycytes/50% nonmyocytes [3]) was immediately
subjected to EHT generation.
Construction of EHT
EHTs were constructed as described previously. [4] Briefly,
acetic acid solubilized collagen type I was mixed with concentrated
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extract, 200 U/mL penicillin, 200 mg/mL streptomycin). The pH
was neutralized by titration with 0.1 N NaOH. Matrigel was
added (10% v/v) if indicated. Finally, cells were added to the
reconstitution mixture, which was thoroughly mixed before casting
in circular molds (inner diameter, 5 mm; outer diameter, 10 mm;
height, 5 mm). Within 3 to 5 days, EHT coalesced to form
spontaneously contracting circular structures and were transferred
on automated stretch devices conventionally constructed in our
laboratory (Fig 1 and Video S1).
Hypoxia – Reoxygenation
To understand if fully developed EHT behaves similar to adult
myocardium under stress, we used hypoxia-reoxygenation to
simulate myocardial ischemia-reperfusion in vivo. For this
purpose, the spontaneously contracting EHT was subjected to
6 h of hypoxia by culturing them with 1% O2 followed by 12 h of
reoxygenation. At the end of experimental protocol the EHT was
randomly assigned to undergo optical mapping to study the
changes in conduction velocity or for protein extraction to study
the changes in pro-survival signaling cascade.
To demonstrate if the EHT could exhibit similar responses of the
adult heart to treatment with pharmacological agents under hypoxic
stresses, the EHT was treated with cyclosporin (CsA, 0.2mM) or
acetylcholine (ACh, 500mM) before hypoxia. We and others
[10,11,12,13] have previously demonstrated the cytoprotective effects
of CsA or ACh on myocardium after acute ischemic injury (Fig 1).
Optical Mapping
EHTs were superfused with warmed Tyrode’s solution (135 mM
NaCl, 5.4 mM KCl, 1.8 mM CaCl2,1 m MM g C l 2,0 . 3 3 m M
NaH2PO4, 5 mM HEPES, and 5 mM glucose) containing the
voltage-sensitive dye di-4-ANEPPS (10 mM; Molecular Probes,
Eugene, OR). After 7 min, the chamber was sealed and the dye was
washed out as described earlier [14]. Action potentials (AP) were
o p t i c a l l ym a p p e du s i n gaC M O S - b a s e dh i g hs p e e da n dh i g hr e s o l u t i o n
optical mapping system (MICAM ULTIMA, Brainvision, Japan).
Protein Preparation and Immunoblotting
As described previously [11,15] the samples obtained at the
end of experiments were prepared for immunoblot analysis.
Extracted proteins were quantified with a BCA Assay Kit
(Sigma). Equal amounts of proteins (50mg of total protein) were
separated by SDS-PAGE, and transferred to a PVDF membrane
(Millipore). After blocking nonspecific sites with 5% non-fat milk
in TBS supplemented with 0.1% Tween20 over night, the
membranes were probed with primary antibodies against
Connexin 43 (1:1000, Zymed Laboratories), Akt (1:1000, Cell
Signaling) and phospho Akt (1:1000, Cell Signaling), BCl-2
(1:1000, Cell Signaling), and a-sarcomeric actin (1:1000, Abcam).
Beta-actin (1:1000, Cell Signaling) was used as loading control of
the protein samples. Anti-rabbit IgG conjugated with horseradish
peroxidase (diluted 1:5000, Santa Cruz) was used as secondary
antibodies and the membranes were finally developed with an
ECL chemiluminescence reagent (Amersham). The samples were
quantified by densitometry using Kodak Gel Logic 100 system
(Kodak, Japan).
Electron Microscopy
Following different protocols, the EHTs were divided into
approximately 1 mm blocks and immediately fixed with cold 2%
glutraldehyde. After 24 hr fixation at 4uC the samples were
postfixed with 1% osmium tetroxide for 1 hr, dehydrated with
increasing concentrations of alcohol (50%, 70%, 80%, 90%, and
100%; three times at each concentration) for 10 min each. Next,
cells were infiltrated with propylene oxide for 15 min, followed by
1:1 propylene oxide: epoxy resin for 4 hr. Samples were then
embedded with fresh epoxy resin into molds and placed in an
80uC oven for 18 hr. Ultrathin sections were stained with uranyl
acetate and lead citrate and were examined under an electron
microscope [16].
Statistical Analysis
Differences between two groups were analyzed using t-test
(paired or unpaired as appropriate). Values are expressed as
Figure 1. Experimental Protocol. Experimental protocol of the study.
doi:10.1371/journal.pone.0009275.g001
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significant for all parameters.
Results
Construction of Functionally Active EHTs
Using the whole cell population from neonatal hearts we
successfully constructed functionally active EHTs (Video S1). At
day 5 after culture, the EHT demonstrated irregular fibrillation
like contractions which became synchronous and regular after
mechanical stretching (Video S1). The functionality of the
constructed EHT was confirmed first using electron microscopy,
showing fully developed adult cardiomyocytes with normally
arranged sarcomeres (Fig 2A). Immunoblotting confirmed the
expression of cardiac specific connexin 43 and a-sarcomeric actin
(Fig 2B). Most importantly, mechanical stretches resulted in
upregulation of these proteins (Fig 2B). Further, optical mapping
showed synchronic conduction velocity as measured by the action
potential recording across constructed EHTs (Fig S1 and Fig 2C).
EHT Responds to Hypoxic Stresses
Next we tested if the constructed EHT could respond to
hypoxic stress in a similar way to the whole heart. For this
purpose, the EHTs were subjected to hypoxia and reoxygenation
to simulate myocardial ischemia in vitro. Similar to the adult
heart [12], hypoxia induced dephosphorylation of gap junctional
protein connexin 43 (Fig 3A) and loss of normal conduction
across EHT (Fig 3B). This was further confirmed by the
molecular analysis of cell survival Akt and Bcl-2, both of which
were downregulated in EHT subjected to hypoxia (Fig 4). Most
importantly, treating EHT with pro-survival ACh or CsA
[10,16], markedly inhibited the hypoxia induced damage to the
EHT (P,0.01, Fig 3 and 4).
Discussion
Cardiac tissue engineering is an emerging field that may hold
great promise for advancing the treatment of heart diseases [17].
EHTs have been developed in the view of myocardial
Figure 2. Characterization of the fully developed EHT. Samples were collected for electron microscopy (A) and western blotting (B1) after
mechanical stretching. Tubulin was used as a loading control. Densitometry analysis was perfomed as explained in the methods. **P,0.001 versus
before stretch. For optical mapping (B2), The EHT was loaded with voltage sensitive dye and images were captured with a CMOS-based high speed
and high resolution optical mapping system.
doi:10.1371/journal.pone.0009275.g002
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strated the feasibility of EHTs in improving the cardiac function
following myocardial injury [18,19,20]. However, to our
knowledge this is the first study demonstrating the novel function
of EHTs as a replacement model to the whole heart, for studying
the response of the heart to any form of stresses, and to screen
the pharmacological compounds for treatment of myocardial
injury.
Figure 3. Response of EHT to hypoxic stress. A. Representative Immunoblotting analysis of connexin 43 in EHTs subjected to hypoxic stresses.
Arrows indicate positions of phosphorylated isoform of connexin 43 (43 kDa) and nonphosphorylated isoform of connexin 43 (41 kDa) bands,
respectively. Quantitative densitometric analysis represents the phosphorylated isoform of connexin 43. Values are mean 6 SD
#P,0.05 versus
normal group and
*P,0.05 versus hypoxic group. N=5 in each group. B. Representative images showing the conduction defect evaluated by optical
mapping, following exposure of EHTs to hypoxia, which was reverted by treatment with ACh. The synchronous conduction was lost in the EHT
subjected to hypoxia. However, treatment with ACh prevented the conduction defect.
doi:10.1371/journal.pone.0009275.g003
Figure 4. Cell survival Cascade analysis. Representative immunoblot and quantitative analysis of Akt (A) and Bcl-2 (B) in EHTs exposed to
hypoxia. Values are mean 6 SD
#P,0.05 versus normal group and
*P,0.05 versus hypoxic group. N=5 in each group.
doi:10.1371/journal.pone.0009275.g004
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by a good experimental model. Rodent models are widely used for
the study of various cardiovascular diseases, especially to study the
effect of long-term pharmacological interventions including long-
term survival studies [21,22]. However, apart from the outstand-
ing cost, the use of animals needs expert skills and long time to
yield reliable results. Moreover, the large number of animals are
required to make reproducible results, especially in experiments
involving pharmacological testing. However, as demonstrated in
this study, the use of EHTs is easy, but at the same time, and does
not compromise the quality of research outcome. From our
experience it is possible to construct more than 5 pieces of EHTs
from a single neonatal heart, which give the possibility to test the
effect of different pharmacological agents on a single heart
preparation. Futhermore, the EHT is useful in reproducing the
effects of stresses and pharmacological agents on conduction
velocity of action potentials, in a similar way to the whole heart. In
addition, as demonstrated in the study, the survival signaling
pathway in EHTs responds in a similar way to the whole heart
under hypoxic stress.
Taken together, fully developed EHTs exhibit the characteris-
tics of adult hearts and when subjected to hypoxia, they respond
identical to the adult myocardium. Although, in vivo experiments
are the golden standard for analysis of functional recovery
following myocardial injury and pharmacological interventions,
the developed EHTs could be used as a replacement for the adult
heart in the situation of acute experimental setting, especially for
studying the effects of stresses and treatment conduction velocity
and molecular expressional changes.
Supporting Information
Figure S1 Mechanical stretch synchronizes the contraction of
engineered heart tissue.
Found at: doi:10.1371/journal.pone.0009275.s001 (2.18 MB TIF)
Video S1 Video demonstrating the construction of engineered
heart tissue.
Found at: doi:10.1371/journal.pone.0009275.s002 (1.78 MB
MP4)
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